1. Introduction {#sec1}
===============

Raynaud\'s phenomenon (RP) affects 3--5% of the population \[[@B1]\] and is characterized by episodic vasospasm of digital arteries causing pallor, cyanosis, and/or rubor upon rewarming. It is caused by poor blood flow to digits, often occurring with cold exposure and stress. The severity of symptoms ranges from mild to severe pain, and in secondary RP there may be ischemic complications. RP can be primary (idiopathic) or secondary. Secondary RP is associated with an underlying disease (often a connective tissue disease {CTD} such as systemic sclerosis {SSc, scleroderma}, systemic lupus erythematosus {SLE}, and Sjogren\'s syndrome).

The exact mechanisms causing RP are unknown, but inflammatory and angiogenic cytokines secreted by circulating cells and endothelial cells (ECs) may stimulate vascular abnormalities that ultimately reduce blood flow. Underlying endothelial dysfunction likely initiates and mediates this pathological process \[[@B2]\]. ECs in RP promote an inflammatory response through elevated production of proinflammatory cytokines \[[@B2]\] and increased expression of adhesion molecules \[[@B3], [@B4]\] and secretion of vasoconstrictor and profibrotic mediators, such as endothelin-1 and angiotensin, instead of vasodilators \[[@B5]\].

Primary RP is most often controlled with lifestyle changes (keeping warm, smoking cessation), whereas secondary RP in patients with SSc frequently requires systemic treatment. Depending on disease severity, the choice of medication includes calcium channel blockers (CCBs), such as nifedipine, and other vasodilators. CCBs in both primary and secondary Raynaud\'s have demonstrated modest benefit; however these medications frequently have side effects such as hypotension, flushing, peripheral edema, and headaches \[[@B6]--[@B8]\]. There is an unmet need for an effective and well-tolerated treatment in moderate-to-severe RP.

One trial suggested that fluoxetine (an antidepressant) was effective in the treatment of both primary and secondary RP \[[@B9]\]. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) which in RP may be improving vascular endothelium \[[@B9]\]. Ketanserin, a selective antagonist of serotonin, has also been studied in RP \[[@B10]\]. Serotonin receptors have been shown to be important in vasospasm in patients with RP \[[@B11]\]. St. John\'s Wort (SJW, *hypericum perforatum*) is a natural herbal product with some SSRI-like properties. In mild-to-moderate depression, SJW appears to be equally effective, with fewer side effects than prescription SSRI drugs \[[@B12]--[@B17]\]. Thus, SJW may be an effective, safe, and well-tolerated alternative treatment for RP via effects on serotonin. In this study, the dose of SJW was selected to be 600 mg a day (given as 300 mg BID). Depression trials have dosed SJW from 300 to as high as 900 mg BID \[[@B12]--[@B17]\], where 300 mg BID was superior to placebo and well tolerated \[[@B16], [@B17]\].

We performed a trial with SJW in subjects with primary and secondary RP. The hypothesis of this trial was that SJW would be more effective than placebo in the treatment of RP, as defined by decreased frequency, duration, and severity of attacks.

2. Methods {#sec2}
==========

2.1. Study Design {#sec2.1}
-----------------

This randomized, double-blinded, placebo-controlled trial was registered at clinicaltrials.gov.ca. It was approved by Health Canada (in the Natural Health Product division). Ethics approval was obtained from the University of Western Ontario Ethics Committee.

2.2. Subjects {#sec2.2}
-------------

Subjects were recruited from a rheumatology clinic over two winters, as Raynaud\'s symptoms are more severe at this time. All subjects had symptomatic RP and were stratified by primary versus secondary Raynaud\'s, and within secondary RP between systemic sclerosis and other connective tissue diseases. Inclusion criteria were primary or secondary RP as diagnosed by a rheumatologist, clinical need for treatment of RP with at least 7 attacks per week over a two-week run in, age at least 16 years, able to provide informed consent, and ability to complete the daily standardized RP symptom diary prior to randomization. The exclusion criteria consisted of a prior allergic reaction to SJW, depression requiring treatment, use of SSRIs or other antidepressants with the exception of low-dose amitriptyline used for reasons other than depression, use of drugs that may interact with SSRIs such as cyclosporine, warfarin, digoxin, and theophylline, clinically significant noncompliance, and anticipated need for surgery (sympathectomy) within 3 months of the trial. Subjects that met these criteria were randomized using computer-based randomization 1 : 1 to receive either SJW dosed at 300 mg twice daily (BID) or a lactose placebo BID for 6 weeks. St. John\'s Wort (SJW) was provided by Webber Pharmaceuticals. SJW was reencapsulated by our research pharmacists who also made the encapsulated placebo. Subjects completed a daily journal with standardized questions about each attack (severity and duration). Using the diary, the number of attacks per day was calculated. They also recorded any potential adverse events (AEs). Every 2 weeks subjects were seen by a study nurse and asked about side effects and digital ulcers, and patient global assessments were performed.

Blood was drawn into EDTA tubes at 0 and 6 weeks post-treatment, immediately spun, and plasma frozen at -80°C for later analysis of 18 inflammatory and angiogenic cytokines using multiplexed immunoassays (Millipore Corp., MA) and ELISA for TGF-*β*1 (BD Biosciences, NJ).

2.3. Efficacy Measures {#sec2.3}
----------------------

Primary outcome measures were the frequency of RP (number of attacks daily), severity of RP on a 0 to 10 scale, duration of RP attacks (in minutes) (from the RP diary), and changes in the levels of inflammatory and angiogenic cytokines between baseline and 6 weeks post-treatment. Secondary outcome measures assessed at the beginning and end of the treatment period were the health assessment questionnaire (HAQ) disability index, patient global assessment of RP, and the presence and location of digital ulcers.

2.4. Sample Size Calculation {#sec2.4}
----------------------------

Using a between-group difference in number of RP attacks at the end of the study of 2.4 attacks per day in placebo and a 45% reduction in attacks in SJW, and assuming an equal SD of 0.75 with 80% power and a two-sided *P* value of 0.05, we would need only 8 patients per group to complete the study. This was an early phase study (the first of SJW in RP), and the data were to direct future potential RP trials with SJW.

2.5. Statistics {#sec2.5}
---------------

Between-group comparisons (SJW compared to placebo) were done using 2-tailed, paired *t*-tests to analyze for significant changes (fold changes) in cytokine levels between baseline and 6 weeks post-treatment. Similar analyses were then performed combining all completers based on patient-reported improvement (≥ or \<50%) in the frequency and severity of attacks, irrespective of treatment allocation, to find a correlation between cytokines and symptoms. Within-group comparisons were done using paired *t*-tests in completers to analyze for significant changes in the frequency, duration, and severity of attacks per day.

3. Results {#sec3}
==========

3.1. Subjects {#sec3.1}
-------------

Thirty-three patients with symptomatic RP were screened (30 females, 3 males) and 25 were randomized (as five had \<7 attacks per week over the two week run in and three did not want to continue in the study). In those randomized, 5 had primary RP and 20 had secondary RP, of whom 11 had SSc and 2 were undifferentiated CTD, 2 SLE, 2 RA, and one each of mixed connective tissue disease, Sjogren\'s syndrome, and dermatomyositis. Eighteen subjects completed the trial (2 had primary RP and 8 with SSc), with 8 on active SJW and 10 on placebo. Adverse events (AEs) were common (57% SJW, 43% placebo), especially headaches. While these AEs were generally mild, there was one serious AE in a subject with secondary RP and scleroderma that involved hospitalization due to atrial fibrillation. Seven who were randomized dropped out, 4 due to AEs (3 on SJW and one on placebo). There were no significant differences between SJW and placebo using ITT and also comparing only the completers.

3.2. Severity, Duration, and Frequency of Attacks {#sec3.2}
-------------------------------------------------

There were no significant differences in the severity, duration or frequency of attacks between the groups. However, there were significant within-group differences observed from beginning to end of the trial in both SJW and placebo groups ([Table 1](#tab1){ref-type="table"} shows the completers only analysis). There were no important differences for the secondary endpoints when comparing SJW to placebo.

The within-group pre- and post-treatment frequency and severity of attacks were not significant in the SJW group. In contrast, within the placebo group, the frequency of attacks per day decreased significantly (*P* = 0.001) as did the severity of attacks (*P* = 0.004). The duration of daily RP attacks decreased significantly with SJW (*P* = 0.002) and also with placebo (*P* = 0.009). The absolute change was numerically less with SJW than placebo. This difference in duration of attacks was further analyzed within the SJW group by the subtype of secondary RP (SSc and other CTD), but not in primary RP as the number of participants was too small. These analyses showed a significant improvement (*P* = 0.033) in the duration of attacks in subjects with secondary RP in the nonscleroderma group.

3.3. Cytokines {#sec3.3}
--------------

There were no significant changes in cytokine levels from pre- to post-treatment between the SJW and placebo. All patients who completed the study were collated (combining SJW and placebo) based on patient-reported scores into ≥ or \<50% improvement in the frequency and then severity of RP attacks to analyze the significance between cytokines and symptoms, irrespective of treatment allocation. Cytokines were analyzed as the percent change relative to baseline and also as mean differences between the start and end of treatment since both types of analyses may have biological relevance.

3.4. Percent Change {#sec3.4}
-------------------

We found that those with a [\>]{.ul}50% improvement in patient-reported frequency of attacks was significantly associated with a larger fold increase in levels of MMP-9 (*P* = 0.027), MIP-1*β* (*P* = 0.045), and VEGF (*P* = 0.002) between baseline and the end of treatment when compared to a \<50% improvement (data not shown). There was no significant correlation between severity of attacks and percent change in cytokine levels.

3.5. Mean Differences {#sec3.5}
---------------------

Comparing subjects who improved by at least 50% to those who did not with respect to the frequency of RP attacks demonstrated significant changes in E-selectin (*P* = 0.049), MMP-9 (*P* = 0.011), G-CSF (*P* = 0.02), and VEGF (*P* = 0.012) ([Table 2](#tab2){ref-type="table"}). Using the same comparison for ≥ or \<50% improvement in severity of attacks, a significant increase in sVCAM-1 (*P* = 0.003), sICAM-1 (*P* = 0.007), and MCP-1 (*P* = 0.004) was observed ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

SJW was not superior to placebo, and in fact, placebo was numerically but not significantly better than SJW on some outcomes. It is likely that shared properties between SSRIs and SJW in the treatment of depression are not similar in RP treatment at the dose studied \[[@B9]\]. SJW should not be pursued for the treatment of RP in a larger trial as there was no biomarker or clinical change that was superior to the placebo group.

There were significant within-group results which underscores that any open-label treatment trial needs to be interpreted with caution in RP as there is likely a large placebo effect or regression to the mean. Even proof-of-concept trials testing new agents in RP should have a double-blinded, randomized trial design.

There are multiple potential reasons why this is a negative trial which could include inefficacy of SJW, underdosing, heterogeneity of the patients, small sample size, inadequate outcome measurements, or spurious results, but there was not even a trend of improvement compared to placebo. Many published trials have combined primary and secondary RP stratifying by type of RP, which we did. We tried to have a more homogenous group of patients to study by using only patients with a high frequency of RP attacks. Also, the majority of patients were secondary RP, so perhaps they are more difficult to treat than primary RP, and in this group the numbers are incredibly small to make any treatment conclusion within this small subset of completers. The SJW dose was at the lower end of what has been used for depression trials but nevertheless the dose we chose had demonstrated efficacy \[[@B16], [@B17]\]. The Raynaud\'s Condition Score (a daily self-assessment questionnaire of RP on an ordinal scale) \[[@B18]\] was not collected within the diaries but at each visit patient global RP assessment was done. Biomarker data also did not demonstrate that SJW is effective in RP. Some biomarkers improved in patients whose RP was better, but they did not improve more in the SJW group compared to placebo. The placebo changes for RP outcomes in this study may have occurred as there is often regression to the mean in RP trials. For instance, when patients enroll in RP trials requiring a large number of attacks, they enter at a high level of RP activity which may decrease over time, and attacks are often related to cold temperature, which may vary over the study as a 6-week long trial started in winter may finish for some patients in spring. However, we cannot infer that SJW was worse than placebo as there were no statistically significant between-group differences and in both allocations there was improvement of RP. The study is too small to comment on individual background medications but patients were in a steady state if they were using calcium channel blockers or losartan for RP. We did not stop a partially effective drug due to the ethics of stopping treatment during winter in patients with more than 7 attacks per week on their current treatment if it was perceived to have partial benefit. We did not find lack of tolerability with other RP medications when adding SJW, but the numbers are too small. SJW does have many potential drug interactions but the Health Canada-approved protocol excluded only drug-SJW interactions which were thought to be of clinical relevance.

AEs were common in this trial, and one SAE in a patient using SJW occurred. Since our incidence of AEs was fairly similar in SJW and placebo, many side effects were likely not related to the study medication.

Patients that reported a [\>]{.ul}50% improvement in the frequency of Raynaud\'s attacks were associated with higher levels of the proangiogenic cytokines, MMP-9, MIP-1*β*, sE-selectin, G-CSF, and VEGF. Similarly, decreased severity of these attacks corresponded to increases in plasma levels of sVCAM-1, sICAM-1, and MCP-1. We did not correct for multiple tests, and some of the changes may be due to within-patient variability of the cytokine levels. However, testing these cytokines may be useful in other proof-of-concept trials with different agents in RP to determine if any are associated with clinically relevant RP outcomes.

St. John\'s Wort was supplied by Webber Pharmaceuticals and gel coated by St. Joseph\'s pharmacy to make an identical placebo. In no way did Webber influence the conduct or results of the trial. D. Malenfant was a medical student who was funded by the Schulich Research Training Program (SRTP).

###### 

Within-group characteristics for frequency, duration, and severity of RP in SJW compared to placebo in the completers. There were no between-group differences.

                                                        Baseline SJW (*N* = 8)   6-Week Followup SJW   Mean difference SJW   *P*-value Within group SJW   Baseline Placebo (*N* = 10)   6-Week Followup Placebo   Mean difference Placebo   *P*-value Within group Placebo
  ----------------------------------------------------- ------------------------ --------------------- --------------------- ---------------------------- ----------------------------- ------------------------- ------------------------- --------------------------------
  Frequency (mean no. of attacks per day)               3.175                    2.4238                .7513                 0.1238                       2.366                         1.353                     1.0130                    0.001
  Duration (mean total of attacks in minutes per day)   28.279                   18.009                10.2703               0.0019                       26.010                        13.510                    12.4992                   0.009
  Severity (scale 0 to 10)                              4.752                    3.785                 .9668                 0.0758                       2.954                         1.947                     1.0066                    0.004

###### 

Within-group comparisons of patient-reported improvements in the frequency of Raynaud\'s attacks and the difference of cytokine levels between pre- and post-treatment. *P* values were calculated using 2-tailed, paired *t*-tests. Data represents mean comparisons of changes in cytokines in those who had more than 50% reduction in frequency (number) of RP attacks compared to those who did not.

  Cytokine        Mean cytokine change   Difference   Std. error difference   *P* value   
  --------------- ---------------------- ------------ ----------------------- ----------- -------
  *sE-Selectin*   5843.8                 −3473.3      9317.1                  4203.1      0.049
  sVCAM-1         134550.6               −14819.9     149370.5                122138.5    0.247
  sICAM-1         8861.6                 −13292.5     22154.1                 17813.4     0.239
  *MMP-9*         68574.0                −104997.8    173571.8                57260.1     0.011
  tPAI-1          −188.4                 −10086.1     9897.7                  7392.6      0.208
  IL-4            −0.2                   0.0          −0.2                    0.2         0.356
  IL-6            −2.6                   0.1          −2.7                    2.9         0.387
  IL-8            −0.4                   −1.1         0.7                     1.9         0.726
  IL-10           0.0                    0.0                                              
  IL-12p70        0.3                    0.1          0.3                     0.3         0.416
  IL-17           0.0                    −0.5         0.5                     0.5         0.363
  Eotaxin         −4.6                   0.6          −5.2                    9.4         0.588
  Basic FGF       1.0                    3.4          −2.5                    2.9         0.408
  *G-CSF*         15.0                   −12.1        27.0                    10.0        0.020
  IFN-*γ*         −13.6                  0.6          −14.1                   21.8        0.531
  IP-10           110.1                  78.9         31.2                    106.8       0.776
  MCP-1           −12.4                  −3.1         −9.3                    20.2        0.654
  MIP-1*α*        −0.4                   0.3          −0.7                    0.5         0.199
  MIP-1*β*        7.1                    −3.5         10.6                    5.5         0.082
  PDGF-BB         −133.4                 −244.1       110.7                   309.2       0.727
  TNF- *α*        −1.0                   2.2          −3.2                    3.1         0.341
  *VEGF*          7.3                    −11.5        18.8                    6.3         0.012
  TGF-*β*1        −2.4                   −4.1         1.7                     2.9         0.565

###### 

Within-group comparisons of patient-reported improvements in the severity of Raynaud\'s attacks and the difference of cytokine levels between pre- and post-treatment. *P* values were calculated using 2-tailed, paired *t*-tests.

  Cytokine      Mean cytokine change   Mean difference   Std. error difference   *P* value   
  ------------- ---------------------- ----------------- ----------------------- ----------- ------
  sE-Selectin   1429.1                 1564.4            −135.3                  6985.0      .985
  *sVCAM-1*     443639.4               −3122.2           446761.6                119191.6    .003
  *sICAM-1*     27421.2                −6596.9           34018.1                 10030.8     .007
  MMP-9         31051.5                −19279.3          50330.7                 106102.6    .645
  tPAI-1        1203.7                 −5840.2           7043.9                  10808.5     .528
  IL-4          0.0                    −0.2              0.2                     0.4         .689
  IL-6          0.0                    −1.6              1.6                     4.5         .724
  IL-8          1.4                    −1.2              2.6                     2.4         .305
  IL-10         0.0                    0.0                                                   
  IL-12p70      −0.1                   0.2               −0.3                    0.4         .447
  IL-17         0.0                    −0.3              0.3                     0.7         .689
  Eotaxin       4.0                    −3.3              7.3                     12.9        .582
  Basic FGF     −1.0                   2.7               −3.7                    3.9         .363
  G-CSF         8.8                    1.3               7.5                     17.7        .680
  IFN-*γ*       9.0                    −10.0             19.0                    30.2        .542
  IP-10         188.5                  78.8              109.7                   144.4       .463
  *MCP-1*       27.8                   −14.7             42.4                    11.4        .004
  MIP-1*α*      0.0                    0.0               0.0                     0.8         .956
  MIP-1*β*      3.1                    2.1               1.0                     8.8         .916
  PDGF-BB       3.0                    −218.6            221.6                   424.4       .612
  TNF-*α*       −0.4                   0.7               −1.1                    4.2         .798
  VEGF          9.5                    −3.4              12.9                    11.0        .265
  TGF-*β*1      −3.5                   −3.1              −0.4                    4.1         .919
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